Biolinerx Stock Price, News & Analysis

BioLineRx Ltd. (NASDAQ: BLRX) will release its unaudited financial results for Q2 2022 on August 16, 2022, before US market opens. Following this, a conference call will be held at 10:00 a.m. EDT, featuring remarks from CEO Philip Serlin. The call can be accessed via the company's Investor Relations page, with dial-in options available. BioLineRx focuses on oncology, with its lead program, Motixafortide, in various trials including one for pancreatic cancer. The company is also developing AGI-134, aimed at multiple solid tumors.

M.S.Q. Ventures announced that its client, BioLineRx (NASDAQ/TASE: BLRX), has entered into a co-development agreement with GenFleet Therapeutics for the cancer treatment Motixafortide in pancreatic ductal adenocarcinoma (PDAC). The agreement involves a Phase 2b clinical trial in China with around 200 patients, aiming to assess the efficacy of Motixafortide combined with anti-PD-1 and chemotherapy. Results from the preceding Phase 2a study suggest potential benefits, and this collaboration is expected to expedite PDAC treatment development.

BioLineRx (NASDAQ: BLRX) has entered a collaboration with GenFleet Therapeutics to conduct a Phase 2b trial of Motixafortide for first-line metastatic pancreatic cancer (PDAC) in China. GenFleet will fund and execute the trial, evaluating Motixafortide combined with anti-PD-1 and chemotherapy against standard chemotherapy. This partnership follows positive results from the Phase 2a COMBAT/KEYNOTE-202 study, which showed improved outcomes in second-line PDAC therapy. BioLineRx retains global rights to Motixafortide and plans to submit a New Drug Application for stem cell mobilization soon.

BioLineRx Ltd. (NASDAQ: BLRX) has appointed Holly W. May as its Chief Commercial Officer, a newly established role, effective June 16, 2022. Ms. May brings extensive experience in commercial strategy, having led 13 product launches, and will focus on the U.S. market for Motixafortide, pending FDA approval. The U.S. market for Motixafortide in stem cell mobilization is projected to be worth $360 million annually. BioLineRx aims to submit a New Drug Application to the FDA in mid-2022, continuing preparations for Motixafortide's launch.

BioLineRx Ltd. (NASDAQ: BLRX) reported its Q1 2022 financial results, highlighting significant progress on Motixafortide's New Drug Application (NDA) for stem cell mobilization, expected to be submitted to the FDA by mid-2022. The company ended Q1 with $50.6 million in cash, sufficient to fund operations into H1 2024. A market assessment estimates a $360 million opportunity in the U.S. for stem cell mobilization. Positive cost-effectiveness results were reported, showing savings of ~$30,000 versus other treatments. The net loss narrowed to $4.9 million from $10.2 million year-over-year.

BioLineRx Ltd. (NASDAQ: BLRX) will announce its unaudited financial results for Q1 2022 on May 11, 2022, before US markets open. A conference call hosted by CEO Philip Serlin is scheduled for the same day at 10:00 a.m. EDT. The call will be accessible via the Company's Investor Relations page. BioLineRx focuses on oncology, with key programs including Motixafortide for cancer therapy and AGI-134, aimed at treating solid tumors. A replay will be available post-call.

BioLineRx Ltd. (NASDAQ: BLRX) announced its 2021 financial results, reporting a net loss of $27.1 million, less than the $30 million loss in 2020. The company holds $57.1 million in cash and equivalents. A significant highlight was the positive outcome of a pharmacoeconomic study for Motixafortide, showing substantial cost savings compared to current treatments. BioLineRx plans to submit an NDA for Motixafortide in mid-2022, targeting a $360 million US market. The company aims for a potential FDA approval and US launch of Motixafortide in 2023.

BioLineRx Ltd. (NASDAQ: BLRX), a biopharmaceutical company focused on oncology, will release its audited financial results for the year ended December 31, 2021 on March 16, 2022, before market opening. A conference call featuring CEO Philip Serlin will occur on the same day at 10:00 a.m. EST. Investors can access a live webcast on the Investor Relations page. The company's lead drug, Motixafortide, is in advanced stages for various cancer treatments.

On March 3, 2022, BioLineRx Ltd. (NASDAQ: BLRX) announced positive findings from a pharmacoeconomic study evaluating the cost-effectiveness of Motixafortide combined with G-CSF compared to plerixafor plus G-CSF in multiple myeloma patients. The study showed approximately $30,000 in net cost savings and improved health resource utilization during autologous stem cell transplantation. CEO Philip Serlin emphasized that these results support Motixafortide as a potential new standard of care. The company plans to file an NDA in mid-2022, targeting a market estimated at over $360 million in the US.